Role of biomarkers in the management of antibiotic therapy : an expert panel review : I - currently available biomarkers for clinical use in acute infections

• Published in: Annals of intensive care 1 (3), 1-8. (2013)
• Main Authors: Dupuy, Anne-Marie, Philippart, Francois, Pean, Yves, Lasocki, Sigismond, Charles, Pierre Emmanuel, Chalumeau, Martin, Claessens, Yann-Eric, Quenot, Jean-Pierre, Gras-Le Guen, Christele, Ruiz, Stéphanie, Luyt, Charles-Edouard, Roche, Nicolas, Stahl, Jean-Paul, Bedos, Jean-Pierre, Pugin, Jérôme, Gauzit, Rémy, Misset, Benoit, Brun-Buisson, Christian
• Format: Publication
• Language: English
• Published: 2013
• Subjects: biomarker; biomarqueur; C-reactive protein; emergency medicine; infection; proADM; procalcitonin; resepsin; Santé publique et épidémiologie; sepsis; septicemie; sTREM-1; suPAR

In the context of worldwide increasing antimicrobial resistance, good antimicrobial prescribing in more needed than ever; unfortunately, information available to clinicians often are insufficient to rely on. Biomarkers might provide help for decision-making and improve antibiotic management. The purpose of this expert panel review was to examine currently available literature on the potential role of biomarkers to improve antimicrobial prescribing, by answering three questions: 1) Which are the biomarkers available for this purpose?; 2) What is their potential role in the initiation of antibiotic therapy?; and 3) What is their role in the decision to stop antibiotic therapy? To answer these questions, studies reviewed were limited to recent clinical studies (<15 years), involving a substantial number of patients (>50) and restricted to controlled trials and meta-analyses for answering questions 2 and 3. With regard to the first question concerning routinely available biomarkers, which might be useful for antibiotic management of acute infections, these are currently limited to C-reactive protein (CRP) and procalcitonin (PCT). Other promising biomarkers that may prove useful in the near future but need to undergo more extensive clinical testing include sTREM-1, suPAR, ProADM, and Presepsin. New approaches to biomarkers of infections include point-of-care testing and genomics.